AEON Biopharma Stock Forecast
NYSE: AEONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 3:23 PM ET
AEON analyst consensus
Consensus (4 analysts)
strong_buy
Avg. price target
$1.82+543.11%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering AEON Biopharma (2026-10-09), 4 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $1.82, with a high estimate of $2.10 and a low estimate of $1.20. The average target implies upside of 543.1% from the current price of $0.283.
The spread between the highest and lowest targets is 75.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for AEON.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 25% |
| Buy | 3 | 75% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $1.20 | +324.03% |
| Average target | $1.82 | +543.11% |
| High target | $2.10 | +642.05% |